Introduction
Influenza viruses cause annual epidemics and occasional pandemics of acute respiratory disease in human populations leading to significant health threats worldwide [1] . Vaccination is the primary intervention method for preventing clinical disease and associated complications [2] [3] . The virus is capable of evading immune recognition through continual antigenic drift of its surface glycoproteins, hemagglutinin (HA) and neuraminidase (NA), resulting in a loss of immunity and vaccine mismatch. As a consequence, monitoring antigenic and genetic variations of circulating influenza viruses are crucial for the selection of annual strains [4] . [5] . Influenza virological surveillance evidenced the co-circulation of the two lineages of the influenza B virus during the same season in many parts of the world, including Europe, Italy and Taiwan [6] - [8] . Since Asia has been considered the gene pool for influenza viruses, the Taiwan Centers for Disease Control (Taiwan-CDC) have been coordinating a laboratory-based virological surveillance network since 2000 to provide updated information about viral characteristics and activities [9] [13] . The selection was based on epidemiological data on the geographic advance of infections, and antigenic and genetic results of recently and most frequently isolated B viruses. These two lineages are distinct antigenically, raising the concern that re-immunization might be required when antigenically altered strains appear [14] - [16] . The current recommendation for TIV vaccination in previously unvaccinated children under the age of 9 years is to receive 2 doses of TIV when vaccinated for the first time and 1 dose annually thereafter. This recommendation assumes effective prime-boosting across related antigens of the 2 influenza A/subtypes, but the declining number of children receiving the second dose 4 weeks later after the first dose makes it logistically challenging.
Since 2008, the Advisory Committee on Immunization Practices (ACIP) recommends annual influenza vaccination for all children of 6 months to 18 years, including all school-aged children [17] . High vaccination coverage of school-aged children is an important public health objective because of the direct benefits to immunized children and the potential indirect protection by reducing student and teacher absenteeism, allowing schools to better accomplish their primary mission and reducing morbidity/mortality for the broader community [18] - [20] . In Taiwan, the national free pediatric immunization programme of TIV has been implemented since 2007, and all children under the age of 9 years from the elementary schools will receive one dose of TIV annually. So far, limited study has been conducted to understand the immunogenicity after receiving different lineages of B antigens in school-aged children less than the age of 9 years-the group considered the primary community spreader of influenza viruses [18] [21] . Most among them are not naïve to influenza viruses and have antibodies against B of both lineages [21] [22] . The current non-randomized sero-epidemiological study conducting during 2008-2010 influenza seasons provided a good opportunity to evaluate the immunological response in schoolaged children who received two antigenic-distinct influenza B virus lineages included in trivalent inactivated influenza vaccine (TIV) in two consecutive seasons.
In order to determine whether immunization with a B viral antigen of one lineage is sufficient to produce antibodies with cross-reactivity against both lineages, we analyzed the haemagglutination inhibition The study protocol based on laboratory data was established to include the paired sera drawn from the study subjects from any two consecutive time periods to define the immune response before and after vaccination or wild-type virus infection. The duration between the date of vaccination and post-vaccination sera collected was in the range of 30 -150 days (median, 75 days). Two questionnaire interviews were also conducted by trained interviewers regarding basic demographic and social contact information, in addition to bi-weekly telephone interviews recording upper respiratory-related symptoms during the influenza seasons. The subjects without clear information on vaccination status or the duration shorter than 4 weeks between two blood samples drawn before and after vaccination will be excluded for further analysis. All subjects gave informed consent and the study was approved by the Medical Ethics Committee of China Medical University (DMR96-IRB-216). For the HI assay, serum samples were pre-treated with receptor destroying enzyme and titrated in two-fold dilutions in phosphate-buffered saline (PBS) with an initial dilution of 1:10. Titres were expressed as the reciprocal of the highest dilution of serum where hemagglutination was prevented. Samples that were below the detection limit (1:10) by HI were assigned a titre of 1:5 for computational purposes in obtaining a four-fold increase and geometric mean titre (GMT) of HI titres. The seroprotection was defined as an HI titre of 1:40 or more. The GMT ratio (GMTR) was calculated by dividing the post-vaccination GMT by the pre-vaccination baseline GMT.
Laboratory Assay

Virological Surveillance
The influenza surveillance network coordinated by Taiwan-CDC covers approximately 75% of the basic administrative units of Taiwan (cities or districts) and routinely collects clinical specimens throughout the years. Throat or nasal swabs from patients with influenza-like illnesses were collected and transported to the laborato-ries of the influenza surveillance network in Taiwan for analysis. On arrival, they were suspended in 1.5 ml of serum-free DMEM medium and filtered through a 0.45 um filter. RNA extraction and subsequent real-time RT-PCR were performed together with virus culture as previously described [25] [26] . This surveillance is performed in an unbiased manner and can provide a detailed record of the timing of the introduction and evolution of a newly emerging variant.
Statistical Analysis
The immunogenicity outcomes, including seroprotection rate and GMTR, were evaluated based on HI titres. The point estimates and 95% confidence intervals (CI) of the immunogenicity outcomes were calculated using a generalized linear model (GLM). The comparisons were made between the vaccination group (yes vs. no), age group (children < 9 vs. ≥9), and different lineage group of influenza B viruses (homologous vs. heterologous). For groups with small numbers of subjects, the non-parametric Wilcoxon rank method was calculated for immunogenicity statistics. A p-value of less than 0.05 represented statistical significance. All statistical analyses were performed using SAS statistical software version 9.2 (SAS Institute, Cary, NC).
Results
Study Subjects
Although the current vaccine recommendation for children less than 9 years of age is to receive 2 doses of TIV, the school children in our study under the coverage of free TIV vaccination programme implemented in Taiwan received only one dose of TIV during the study period. All subjects were divided into two groups: <9 and ≥9 years old to evaluate the differences in immunological responses before and after vaccination. Basic demographic data, including age, gender, residential area and vaccination status of the 148 and 198 school-aged children from two consecutive seasons were described in Table 1 
Virological Surveillance
As shown in Figure 1 Table 2 . During the 2008-09 season, the sero-protection rate (66.7%) post-vaccination in vaccinated subjects less than 9 years was significantly higher for the vaccine strain than that (19.4%) for the heterologous wild-type strain from different lineage, with statistical significance (p < 0.05). A similar result was also observed in children ≥9 years old after receiving TIV vaccinations. To understand if the sero-protection rate post-vaccination was affected by the baseline pre-vaccination titre, the pre-vaccination sera during the 2009-10 season were obtained. For the 2009/10 B/Victoria vaccine antigen, the sero-protection rate in vaccinated subjects were 44.8%, which was significantly lower than those in unvaccinated subjects with 82% (p < 0.05) ( Table 2) . Although the sero-protection rates against the vaccine and heterologous wild-type strains before receiving TIV were equivalently low in the vaccinated group, children under age 9 receiving one dose of 2009/10 TIV also demonstrated significantly higher sero-protection rate of 69% against the homologous vaccine antigen from the same B/Victoria lineage than that of 27.6% against the heterologous wild-type antigen from the other B/Yamagata lineage. However, no differences in the sero-protection rate were observed between different lineage antigens in children ≥9 years and the sera obtained during postseason in both season years.
Fold Increase of HI before and Post-Vaccination
Since the sero-protection rate post-vaccination was dependent on the pre-vaccination antibody titre, the change in antibody titre from before and after vaccination was further compared by GMTR to provide information on the vaccination effect. Post-vaccination with one dose of 2009/10 TIV in children under age 9 in years induced significantly higher immunological response to the homologous antigens from B/Victoria lineage with GMTR of 1.82 and 1.13 in vaccinated subjects, compared to the un-vaccinated subjects with GMTR of 0.57 and 0.68 for both strains, B/Brisbane/60/2008 and B/Taiwan/5908/2009, respectively (p < 0.05) (Figure 2) . However, a contradicting result of the antibody response to the heterologous B/Yamagata lineage antigen was observed with GMTR 0.73 in the vaccinated group, compared to 1.07 in the unvaccinated group with statistical significance (p < 0.05). No difference in GMTR post-2009-10 TIV vaccination in children ≥9 years old was observed.
Discussion
In the current study, we followed school-aged children with a well-defined vaccination history to assess subsequent immunological responses to TIV containing the alternate B/Lineage. Our results revealed that children under the age of 9 years in years receiving TIV showed higher HI titres and sero-protection rates of homologous strains from the same lineage than those of heterologous strains from the other lineage while no differences were observed for children in the older age group (≥9 years old). Since 2008, the ACIP recommends annual influenza vaccination for all children of 6 months to 18 years old, including all school-aged children [17] . The results shown in our study provided important information for countries which are planning, or currently implementing the TIV immunization programme in school-aged children.
Influenza B viruses currently circulating worldwide are of two distinct evolutionary hemagglutinin lineages, B/Yamagata and B/Victoria [13] [27] [28] . The distinct antigenicity between B/Yamagata and B/Victoria lineages has also been established based on antisera produced in ferrets, which were found to be highly specific against the homologous lineage with little or no cross-reactivity, suggesting a remarkable antigenic difference between these two lineages [7] [29] [30] . The results were further supported by the lack of cross-reactivity and neutralization activity observed in immunologically naïve volunteers [16] . Since the current trivalent influenza vaccines contain only one B vaccine antigen, the mismatch between vaccine and wild-type antigens and the concurrent appearance of influenza B virus of both lineages during the same winter season are of major concern [14] . The question has been raised as to whether both lineages of B antigen should be represented in the annual influenza vaccine formulation. In this study, we examined whether immunization with a B viral antigen of one lineage is sufficient for producing antibodies with cross-reactivity against both lineages of B viruses. Our results confirmed that children receiving TIV showed higher HI titres and sero-protection rates of homologous strains from the same lineage than those of heterologous strains from the other lineage-either post-vaccination or post-influenza season. The need for the quadrivalent TIV requires further consideration.
Influenza B virus infections and immunizations often produce relatively low HI titres. This effect is not only the result of strain variability but also the method of measuring HI antibodies. Previous studies suggested a more sensitive but less specific assay when applying antigens from influenza B viruses after disruption by treatment with an organic solvent such as ether [31] [32] . The HI titres obtained with antigens after ether or detergent disruption correlate extremely well with neutralization antibody titres, and the HI titres at dilutions exceeding 1:32 after immunization with detergent-disrupted antigens can be associated with protection against illness and infection [31] [33] . In our study, sero-protection rates in subjects after immunization in 2008-09 and 2009-10 seasons were shown to be only 69% and 64% by measuring HI with non-disrupting B viruses as depicted in Table 2 .
Since the presence of a HI antibody is the best surrogate measure of protection and the desired outcome of immunization [34] , the antibody responses detected by HI with non-detergent-disrupted antigens suggest that the sero-protection rates against influenza B virus strains can be under-estimated in our study subjects.
The lower antibody response to the heterologous B/Yamagata lineage antigen among the vaccinated subjects during 2009-10 season as shown above could be related to different priming histories as suggested by previous Although the sample size was small, the results revealed that receiving vaccination of both lineages in two consecutive years showed a significantly higher GMT of HI (107.67; 95% CI: 72.5 -144.9) against the vaccine strain post vaccination compared with children having no vaccination (35.54; 95% CI: 24.9 -51.5) for children under the age of 9 years, with statistical significance (p < 0.05) (data not shown). The significant differences between previous and the current studies included age of the study subjects and a 2-dose schedule was administered and repeated during the season that influenza B/Lineage changed. Evaluation of cohorts of children with a defined history of prior influenza B/Lineage prime-boost experiences across additional seasons will therefore be important for confirming these results and understanding their clinical relevance.
The main limitation of our study relates to the small sample sizes among subsets of the participants receiving alternating TIV, which reduced both the statistical power and precision. Furthermore, the sample bias could not be excluded since the current study design was non-randomized and different exposure experiences between vaccinated and unvaccinated groups might confound the results. Although influenza B was not a major contributor to virus circulation in Taiwan during the span of these sequential studies as shown in Figure 1 , low level transmission in the community was still possible even though the HI titres in post-season sera were similar between vaccinated and non-vaccinated groups. Particularly, children are usually asymptomatic once infected by influenza viruses, and are therefore considered the primary community spreaders of the viruses [19] [37] [38] . At baseline antibody titres before vaccination during 2009-10 season (Table 2) , a lower level of GMT and seroprotection rate for children under the age of 9 years in vaccinated group than that in un-vaccinated group was observed, which suggested asymptomatic infections among un-vaccinated subjects. Finally, we also cannot rule out the observations in this study could be particular to the specific influenza B strains and further evaluation in additional seasons is therefore warranted. 
Different lineages of B antigen
The burden of influenza B infection falls mostly on children although the overall mortality rates associated with influenza B infection were less than those of A/H3N2, but greater than those of A/H1N1 [39] - [41] . In this study, the significantly higher HI titres and sero-protection rates of homologous strains from the same lineage than those of heterologous strains from the other lineage were showed among children under the age of 9 years in years after receiving TIV, while no differences were observed for children in the older age group (>9 years old). Our finding provides both practical and scientific implications for the evaluation of influenza immunization programmes in school-aged children with more diverse exposures and antibody population of immunologic experience to both influenza B lineages.
